Five-year risk of recurrence following treatment of CIN2, CIN3, or AIS: performance of HPV and Pap cotesting in post-treatment management

Lignende værker

• Benchmarking CIN3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines
  af: Katki, Hormuzd A., et al.
  Udgivet: (2013)
• Five-year risks of CIN2+ and CIN3+ for women with HPV-positive and HPV-negative LSIL Pap results
  af: Katki, Hormuzd A., et al.
  Udgivet: (2013)
• Five-year risk of CIN3+ and cervical cancer for women with HPV-positive and HPV-negative high-grade Pap results
  af: Katki, Hormuzd A., et al.
  Udgivet: (2013)
• Five-year risk of CIN3+ and cervical cancer for women who test Pap-negative, but are HPV-positive
  af: Katki, Hormuzd A., et al.
  Udgivet: (2013)
• Five-year risk of CIN3+ and cervical cancer for women with HPV testing of ASC-US Pap results
  af: Katki, Hormuzd A., et al.
  Udgivet: (2013)